RETEVMO

This brand name is authorized in Israel, Japan, United States

Active ingredients

The drug RETEVMO contains one active pharmaceutical ingredient (API):

1 Selpercatinib UNII CEGM9YBNGD - SELPERCATINIB

Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC50 values ranging from 0.92 nM to 67.8 nM. In in vitro and in vivo tumor models, selpercatinib demonstrated anti-tumor activity in cells harboring constitutive activation of RET protein resulting from gene fusions and mutations, including CCDC6-RET, KIF5B-RET, RET V804M, and RET M918T. Read about Selpercatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RETEVMO Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX22		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9243, 9244
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291075M1027, 4291075M2023
Country: US	FDA, National Drug Code	Identifier(s): 0002-2980, 0002-3977